Search

Your search keyword '"Wagner, G. L."' showing total 15 results
Start Over Author "Wagner, G. L."
15 results on '"Wagner, G. L."'

1. High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial)

Author

Zegers, C. M. L., Swinnen, A., Roumen, C., Hoffmann, A. L., Troost, E. G. C., van Asch, C. J. J., Brandts, L., Compter, I., Dieleman, E. M. T., Dijkstra, J. B., Granzier, M., Hendriks, M., Hofman, P., Houben, R. M. A., Ramaekers, B., Ronner, H. E., Rouhl, R. P. W., van der Salm, S., Santegoeds, R. G. C., Verhoeff, J. J., Wagner, G. L., Zwemmer, J., Schijns, OEMG, Colon, A. J., and Eekers, D. B. P.

Published
2024
Full Text
View/download PDF

2. Value of ultra-high field MRI in patients with suspected focal epilepsy and negative 3 T MRI (EpiUltraStudy): protocol for a prospective, longitudinal therapeutic study

Author

van Lanen, R. H. G. J., Wiggins, C. J., Colon, A. J., Backes, W. H., Jansen, J. F. A., Uher, D., Drenthen, G. S., Roebroeck, A., Ivanov, D., Poser, B. A., Hoeberigs, M. C., van Kuijk, S. M. J., Hoogland, G., Rijkers, K., Wagner, G. L., Beckervordersandforth, J., Delev, D., Clusmann, H., Wolking, S., Klinkenberg, S., Rouhl, R. P. W., Hofman, P. A. M., and Schijns, O. E. M. G.

Published
2022
Full Text
View/download PDF

3. Hyperspectral X-ray Imaging with TES Detectors for Nanoscale Chemical Speciation Mapping

Author

Carpenter, M. H., Croce, M. P., Baker, Z. K., Batista, E. R., Caffrey, M. P., Fontes, C. J., Koehler, K. E., Kossmann, S. E., McIntosh, K. G., Rabin, M. W., Renck, B. W., Wagner, G. L., Wilkerson, M. P., Yang, P., Yoho, M. D., Ullom, J. N., Bennett, D. A., O’Neil, G. C., Reintsema, C. D., Schmidt, D. R., Hilton, G. C., Swetz, D. S., Becker, D. T., Gard, J. D., Imrek, J., Mates, J. A. B., Morgan, K. M., Yan, D., Wessels, A. L., Cantor, R. H., Hall, J. A., and Carver, D. T.

Published
2020
Full Text
View/download PDF

12. Actinide (Pu, U) interactions with aerobic soil microbes and their exudates: Fundamental chemistry and effects on environmental behavior.

Author

Neu, M. P., Ruggiero, C. E., Johnson, M. T., Fairlee, J. R., Matonic, J. H., Vanderberg, L. A., Hersman, L. E., He, L., Cox, M. M., Chitwood, D. J., Gladden, P. D., and Wagner, G. L.

Subjects
ACTINIDE elements, AEROBIC bacteria, SIDEROPHORES, PLUTONIUM
Abstract

To understand the environmental behavior of metals we must consider a tremendous range of phenomena, from simple individual reactions, such as ligand complexation and solubility equilibria, to quite complicated and collective processes, such as metal-mineral-microbial interactions. Because of pressing contamination problems at DOE sites and the paucity of relevant actinide chemistry knowledge, research is needed in this entire range of science. The determination and evaluation of key thermodynamic data for actinide species and the development of geochemical, hydrological, and environmental transport models are progressing. In contrast, we know almost nothing about how actinides interact with microorganisms. Ubiquitous microorganisms can absorb, reduce, oxidize, solubilize, or precipitate actinides, thereby affecting their speciation, solubility, bioavailability, and migration. These effects are due to both direct and indirect interactions, such as sorption to the cell wall and reaction with microbial byproducts, respectively. Our goal is to fully characterize specific microbial-actinide interactions, both to develop this area of fundamental research and to determine how the interactions may be exploited to affect environmental actinide mobility/immobility and remediation efforts. © 2000 American Institute of Physics. [ABSTRACT FROM AUTHOR]

Published
2000

13. Levetiracetam: preliminary experience in patients with primary brain tumours.

Author

Wagner GL, Wilms EB, Van Donselaar CA, and Vecht ChJ

Subjects
Brain Neoplasms complications, Follow-Up Studies, Glioma complications, Humans, Levetiracetam, Piracetam adverse effects, Prospective Studies, Seizures etiology, Brain Neoplasms drug therapy, Glioma drug therapy, Piracetam analogs & derivatives, Piracetam therapeutic use, Seizures drug therapy
Published
2003
Full Text
View/download PDF

14. [Levetiracetam: an anti-epileptic drug with interesting pharmacokinetic properties].

Author

Wagner GL, Wilms EB, and Vecht ChJ

Subjects
Anticonvulsants adverse effects, Anticonvulsants therapeutic use, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, Humans, Levetiracetam, Piracetam adverse effects, Piracetam therapeutic use, Treatment Outcome, Anticonvulsants pharmacokinetics, Epilepsies, Partial drug therapy, Piracetam analogs & derivatives, Piracetam pharmacokinetics
Abstract

Levetiracetam is a new anticonvulsant for adjunctive treatment of partial epilepsy. It is well tolerated, with no significant risks, at a dose of 1000-3000 mg/day in adults. The efficacy (> 50% reduction in attacks) in refractory partial epilepsy is 22-40%, depending on the dose. Efficacy was also seen with levetiracetam monotherapy in more than half of the positive responders. Levetiracetam does not cause induction or inhibition of the P450 enzyme system or other enzyme systems, there is no active metabolite and it exhibits almost no protein binding. These factors mean that this drug undergoes no significant interactions with other medication and appears suitable for elderly patients and for conditions requiring complex pharmacotherapy. Compared with other recently registered anti-epilepsy drugs, levetiracetam appears promising in terms of efficacy, tolerability and pharmacokinetics. The simple dosing schedule is an additional benefit.

Published
2002

15. Transcranial magnetic stimulation in patients with cervical spondylotic myelopathy: clinical and radiological correlations.

Author

Tavy DL, Wagner GL, Keunen RW, Wattendorff AR, Hekster RE, and Franssen H

Subjects
Adult, Aged, Electric Stimulation, Evoked Potentials, Female, Humans, Male, Middle Aged, Motor Activity physiology, Neck, Radiography, Spinal Cord physiopathology, Spinal Cord Compression diagnostic imaging, Spinal Cord Diseases physiopathology, Transcranial Magnetic Stimulation, Spinal Cord Diseases diagnosis, Spinal Cord Diseases etiology, Spinal Osteophytosis complications
Abstract

Motor evoked potentials (MEPs) were studied in 28 patients with cervical spondylotic myelopathy. MEPs after cortical stimulation were abnormal in 27 patients, the responses in the leg muscles being affected the most often. Clinically asymptomatic motor lesions were detected in 7 patients (25%). The central motor conduction time (CMCT) for the abductor digiti minimi muscles correlated significantly with the clinical disability, whereas the radiological findings did not correlate with the clinical and neurophysiological parameters. In 9 patients MEPs were also recorded in the biceps muscles. The 7 patients with an abnormal CMCT for the biceps muscles had the most severe stenosis at the C-4-C-5 level or higher. The 2 patients with normal MEPs of the biceps muscles both had a stenosis at the C-5-C-6 level. The results of this study suggest that MEPs are useful for detecting spinal cord dysfunction and for localizing the level of the lesion. Some recommendations regarding the possible use of MEPs in the clinical evaluation of patients with cervical spondylotic myelopathy are given.

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results